Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naïve or Previously Treated Patients with HCV Genotype 1 or 3 Infections

Posted on May 27, 2016 by Edward J. Gane, Christian Schwabe, Robert H. Hyland, Yin Yang, Evguenia Svarovskaia, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Catherine A. Stedman

We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection.

This entry was posted in News. Bookmark the permalink.